Anthracycline Antibiotics in Cancer Therapy: Proceedings of by F. S. Philips (auth.), Franco M. Muggia, Charles W. Young,

By F. S. Philips (auth.), Franco M. Muggia, Charles W. Young, Stephen K. Carter (eds.)

F. M. MUGGIA whilst confronted with the inadequacies of present melanoma therapy, we wish to examine what the longer term could carry. ordinarily, we take without any consideration the previous, who prefer study into absolutely new parts. besides the fact that, the power improvement of fertile soil may well yield astonishing rewards should you decide to construct at the wisdom of the past--hence, this symposium on anthracycline antibiotics. even though the anthracycline antibiotics symbolize a lot of the current and way forward for melanoma therapy, their genuine use c stretches again slightly 20 years to the pioneering efforts of Aurelio Di Marco, who characterised the antitumor houses of daunomycin and adriamycin. * The scientific software of those compounds heralded a decade of pleasure between oncologists facing pediatric tumors, breast melanoma, leukemias, and lymphomas, and opened new wish for sufferers troubled with sar­ comas and quite a few different tumors that were deemed - sistant to chemotherapy. those successes have been tempered with the conclusion that the antitumor impression of anthracyclines should be accomplished now and then in basic terms on the very excessive fee of risking cardiac decompensation and, virtually always, with the prevalence of alopecia and different acute toxicities. This list of previous achievements and difficulties has slowly given strategy to a gift more and more illuminated by means of our skill to change the distressing toxicities of those brokers. designated medical experiences supplemented through creative laboratory versions have steadily elucidated mechanisms and threat components im­ plicated within the cardiomyopathy.

Show description

Read or Download Anthracycline Antibiotics in Cancer Therapy: Proceedings of the International Symposium on Anthracycline Antibiotics in Cancer Therapy, New York, New York, 16–18 September 1981 PDF

Similar cancer books

Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets

One of many major reasons of failure within the therapy of breast melanoma is the intrinsic presence of, or improvement of, drug resistance by means of the melanoma cells. contemporary reports at the mechanisms of melanoma drug resistance have yielded very important details highlighting either how tumour cells might break out those healing constraints and that drug resistance may perhaps additional impinge on tumour cellphone capabilities that could finally advertise an opposed phone phenotype.

An Omics Perspective on Cancer Research

Omics is an rising and interesting zone within the box of technological know-how and medication. a number of promising advancements were elucidated utilizing omics (including genomics, transcriptomics, epigenomics, proteomics, metabolomics, interactomics, cytomics and bioinformatics) in melanoma examine. the advance of high-throughput applied sciences that allow the answer of decoding melanoma from better dimensionality will supply a data base which adjustments the face of melanoma figuring out and therapeutics.

Cancer Active Immunotherapy: Immunoprophylaxis and Immunorestoration

I want to thank all my co-workers who've collaborated with me, from 1963 previously, in organic and scientific study within the box of melanoma energetic immunotherapy, of its immuno­ prevention and immunorestoration. they're going to frequently be quoted during this publication. i'm quite thankful to people who have helped me to write down it through reviewing a few chapters: D.

Extra resources for Anthracycline Antibiotics in Cancer Therapy: Proceedings of the International Symposium on Anthracycline Antibiotics in Cancer Therapy, New York, New York, 16–18 September 1981

Example text

C) Evaluated by bioassay on lung of mice killed 20-26 days after tumor implant into footpad. 05; ...... 01, Mussett test. < The model chosen was the MS-2 sarcoma (originally derived from a MSV-induced sarcoma), which spontaneously metastasizes to the lung (13). OX is active against lung metastases, particularly when administered in combination with other chemotherapeutic drugs like the antimetastatic agent ICRF-159, before the time of surgical tumor amputation (Table 3) (22). 3. tological malignancies.

V. on Day 1 is definitely more active than DNR and DX, and it is also active against the late tumor, while DNR and DX are not. -injected L1210 leukemia was also observed with 4-demethoxydoxorubicin (2), and seems therefore a general property of 4-demethoxyanthracyclines. It has been reported that 4-dmONR is two times more active than DNR and 3-4 times more active than OX on DNA and RNA synthesis of L1210 leukemia cells in vitro (45). p. injected anthracyclines (48). Cell uptake and intracellular distribution of 4-demethoxyanthracyclines must also be considered.

1980. Tumori, 66, 689. 35. Isetta AM, Trizio D. 1981. 12th Int. , Florence, July 19-24, 1981, Abstracts, 115. 36. Robustelli della Cuna G, Pavesi L, Cuzzoni Q, Ganzina F, th Tramarin R. 1981. 12 Int. Congress Chemother, Florence, July 19-24, 1981, Abstracts, 75. 37. , Bonadonna G. Cancer Chemother. Pharmacol. (submitted). 38. Natale M, Brambilla M, Lucchini S, Martini A, Moro E, Pacciarini MA, Tamassia V, Vago G, Trabattoni A. 1981. th 12 Int. , Florence, July 19-24, 1981, Abstracts, 114. 39. Hourteloup and the Clinical Screening Cooperative Group of EORTC.

Download PDF sample

Rated 4.75 of 5 – based on 50 votes